We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Smoking Cessation in Groups and With Tobacco Pastils

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00265460
Recruitment Status : Completed
First Posted : December 14, 2005
Last Update Posted : September 15, 2009
Information provided by:
University Hospital, Gentofte, Copenhagen

Brief Summary:
The purpose of this trial is to examine if smokeless tobacco combined with group support might increase smoking cessation rate compared with groups support in smokers.

Condition or disease Intervention/treatment Phase
Smoking Drug: Oliwer Twist smokeless tobacco (tobacco) Phase 2

Detailed Description:
The purpose of this trial is to examine if smokeless tobacco (Oliwer Twist) combined with group support (15-20 per group) might increase smoking cessation rate compared with groups support cold turkey in smokers.The test product should be used for 7 weeks. Seven group meetings are planned during the first 3 months followed bu follow-up sessions after 6 and 12 months. The design is open, randomized. Assessment of ECG, blood pressure, body-weight, carbon monoxide,lung function, stress, quality of life,withdrawal symptoms,adverse events and plasma nicotine, cotinine and thiocyante at entry and after 4 weeks etc.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 240 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 2 Study of Smoke Free Tobacco and Group Support for Smoking Cessation
Study Start Date : March 2005
Study Completion Date : November 2006

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Primary Outcome Measures :
  1. Continuous Smoking cessation quit rate after 6 and 12 months

Secondary Outcome Measures :
  1. Side effects from tested tobacco product
  2. Intake of nicotine and thiocyanate

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   25 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • smoking > 13 cigarettes/day
  • healthy (allowed: hypertension, diabetes type 2, mild asthma/COPD, hypercholesterolemia)
  • motivated for cessation
  • motivated to use tobacco pastils
  • motivated for group support

Exclusion Criteria:

  • severe diseases
  • psychiatric diseases
  • using antipsychotic drugs
  • used NRT/bupropion in the last 3 months
  • consuming > 6 drinks/day
  • pregnant/lactating
  • stopped smoking more than 2 days during last 3 months

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00265460

Dept. pulmonary medicine Y, Gentofte University Hospital
Copenhagen, Hellerup, Denmark, 2900
Sponsors and Collaborators
University Hospital, Gentofte, Copenhagen
Study Chair: Philip Tønnesen, M.D., Ph.D. Chair dept. pulm. medicine, Gentofte Hospital

ClinicalTrials.gov Identifier: NCT00265460     History of Changes
Other Study ID Numbers: Tonga.2005.00.
First Posted: December 14, 2005    Key Record Dates
Last Update Posted: September 15, 2009
Last Verified: September 2009

Keywords provided by University Hospital, Gentofte, Copenhagen:
smoking cessation,
smokeless tobacco,

Additional relevant MeSH terms:
Ganglionic Stimulants
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Nicotinic Agonists
Cholinergic Agonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Respiratory System Agents